NU51CK000344
Cooperative Agreement
Overview
Grant Description
New Jersey Department of Health ELC Program - Applicant's Jurisdictional Overview and Main Challenges:
New Jersey’s diversity is a strength.
The state’s 9.2 million residents, distributed in 21 counties and 565 municipalities, boast remarkable diversity in terms of race/ethnicity, culture, and languages spoken.
New Jersey is the most densely populated state in the nation with 1,263 residents per square mile and is 11th among states with the most multi-generational housing.
New Jersey ranks third in the nation with the highest percentage of individuals who are foreign-born.
Nearly one-third of all New Jerseyans reported speaking a language other than English at home.
This diversity contributes to the complexity of, and need to, serve marginalized populations.
New Jersey's proximity to the New York City and Philadelphia metropolitan areas continues to position it as a key location for emerging health challenges in the Northeast and across the United States.
The presence of Newark Liberty International Airport, along with other major transportation hubs, places New Jersey at a strategic point for public health monitoring, especially for infectious diseases, as evidenced in early 2020 when New Jersey was an epicenter for the emerging COVID-19 pandemic.
NJ’s mortality rate has seen fluctuations, particularly due to the COVID-19 pandemic.
Heading into the COVID-19 pandemic, the death count and rate among New Jersey residents had been steadily declining for decades.
New Jersey’s age adjusted death rate dropped below that of the U.S. in the mid-to late-1990s and continued to remain below the U.S. rate.
Influenza and pneumonia are the most common cause of death from infectious diseases.
With the arrival of the pandemic, NJ saw our age adjusted death rate for these conditions rise from 10.9/100,000 in 2019 to 14.0/100,000 in 2020.
In 2020, there were approximately 95,715 deaths, far exceeding the average 76,000 annual deaths of previous years.
Given New Jersey's active international airport and the commuting patterns of its population, the state remains vigilant about imported diseases, including ZIKA and multidrug-resistant organisms (MDROs).
The state's public health strategies prioritize addressing these concerns, alongside the continued threat of vector-borne diseases, to protect the well-being of its diverse and densely populated communities.
NJ is also addressing the increasing threat of mosquito-borne diseases due to climate change.
See application background & overview for complete high-level overview of NJ's ELC CK24 application.
New Jersey’s diversity is a strength.
The state’s 9.2 million residents, distributed in 21 counties and 565 municipalities, boast remarkable diversity in terms of race/ethnicity, culture, and languages spoken.
New Jersey is the most densely populated state in the nation with 1,263 residents per square mile and is 11th among states with the most multi-generational housing.
New Jersey ranks third in the nation with the highest percentage of individuals who are foreign-born.
Nearly one-third of all New Jerseyans reported speaking a language other than English at home.
This diversity contributes to the complexity of, and need to, serve marginalized populations.
New Jersey's proximity to the New York City and Philadelphia metropolitan areas continues to position it as a key location for emerging health challenges in the Northeast and across the United States.
The presence of Newark Liberty International Airport, along with other major transportation hubs, places New Jersey at a strategic point for public health monitoring, especially for infectious diseases, as evidenced in early 2020 when New Jersey was an epicenter for the emerging COVID-19 pandemic.
NJ’s mortality rate has seen fluctuations, particularly due to the COVID-19 pandemic.
Heading into the COVID-19 pandemic, the death count and rate among New Jersey residents had been steadily declining for decades.
New Jersey’s age adjusted death rate dropped below that of the U.S. in the mid-to late-1990s and continued to remain below the U.S. rate.
Influenza and pneumonia are the most common cause of death from infectious diseases.
With the arrival of the pandemic, NJ saw our age adjusted death rate for these conditions rise from 10.9/100,000 in 2019 to 14.0/100,000 in 2020.
In 2020, there were approximately 95,715 deaths, far exceeding the average 76,000 annual deaths of previous years.
Given New Jersey's active international airport and the commuting patterns of its population, the state remains vigilant about imported diseases, including ZIKA and multidrug-resistant organisms (MDROs).
The state's public health strategies prioritize addressing these concerns, alongside the continued threat of vector-borne diseases, to protect the well-being of its diverse and densely populated communities.
NJ is also addressing the increasing threat of mosquito-borne diseases due to climate change.
See application background & overview for complete high-level overview of NJ's ELC CK24 application.
Awardee
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding Agency
Place of Performance
New Jersey
United States
Geographic Scope
State-Wide
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 459546% from $2,000 to $9,192,930.
New Jersey Department Of Health was awarded
New Jersey Health Challenges: Diversity Strength & Disease Monitoring
Cooperative Agreement NU51CK000344
worth $9,192,930
from National Center for Emerging and Zoonotic Infectious Diseases in August 2024 with work to be completed primarily in New Jersey United States.
The grant
has a duration of 5 years and
was awarded through assistance program 93.317 Emerging Infections Programs.
The Cooperative Agreement was awarded through grant opportunity Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases (ELC).
Status
(Ongoing)
Last Modified 9/24/25
Period of Performance
8/1/24
Start Date
7/31/29
End Date
Funding Split
$9.2M
Federal Obligation
$0.0
Non-Federal Obligation
$9.2M
Total Obligated
Activity Timeline
Transaction History
Modifications to NU51CK000344
Additional Detail
Award ID FAIN
NU51CK000344
SAI Number
NU51CK000344-830545626
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
State Government
Awarding Office
75CDC1 CDC Office of Financial Resources
Funding Office
75CVL0 CDC NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES
Awardee UEI
MQKPEU6D1BT5
Awardee CAGE
3MWJ7
Performance District
NJ-90
Senators
Robert Menendez
Cory Booker
Cory Booker
Modified: 9/24/25